Sudden cardiac death (SCD) is a major cause of mortality in industrialized countries and
represents a major health issue. The survival rate after out-of-hospital cardiac arrest
(OHCA) is only 10-15%, regardless of first recorded rhythm. Prior heart disease is a major
risk factor for sudden cardiac arrest (SCA), and coronary artery disease (CAD) is the most
common underlying cause. A better understanding of pathophysiological mechanisms occurring
during cardiac arrest (CA), earlier diagnosis of underlying cause as well as identification
of risk factors related to CA may improve patient treatment and increase survival. In our
out-of-hospital cardiac arrest (OHCA)-study, we intend to investigate whether biomarkers,
such as copeptin, hs-cTnT and NT-proBNP in addition to clinical evaluation may improve risk
stratification and supply information related to pathophysiology.
Furthermore, we intend to gather additional pathophysiological information related to
coagulation activation in CA and cardiopulmonary resuscitation (CPR), as intravascular
thrombosis may impair microcirculation and reduce end-organ blood flow which is associated
with a poor prognosis. We intend to study coagulation activation during and immediately after
SCA with regard to outcome, and assess the contribution of the intrinsic system, measured
together with that of the extrinsic system.
Low levels of n-3 fatty acids (FA) are reported as a risk factor for SCD. Red blood cell
eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) may serve as a useful surrogate of
cardiac omega-3 fatty acid status. The exact mechanism by which FAs might protect against
serious cardiac arrhythmias is not known, but they are expected to exert a membrane
stabilizing effect during an ischemic episode. In our study we intend to evaluate the
association between ventricular fibrillation (VF) and the content of EPA and DHA in red blood
cells. Furthermore, as vitamin D is associated with n-3 FAs in the diet, we also aim at
investigating the association between 25-hydroxy (OH)-vitamin D and VF.
Other: Group 1
Other: Group 2
Other: Group 3
Other: Group 4
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02886273
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Age > 18 years
OHCA of assumed cardiac etiology
Documented first recorded heart rythm
Evidence of non-cardiac death (including cerebral etiology and pulmonary embolism)
OHCA due to cardiac tamponade.
All locations for NCT02886273
Stavanger University Hospital
Stavanger, Rogaland, Norway, 4011
View full eligibility
Tris trial is registered with FDA with number: NCT02886273. The sponsor of the trial is Helse Stavanger HF and it is looking for 116 volunteers for the current phase.
Official trial title: DIagnostics, RBC Levels of n-3 Fatty Acids and Serum Vitamin D in Patients With Out-of-Hospital Cardiac Arrest (OHCA)
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.